These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27113165)

  • 1. Characterization of serum antibodies from women immunized with Gardasil: A study of HPV-18 infection of primary human keratinocytes.
    Wang HK; Wei Q; Moldoveanu Z; Huh WK; Vu HL; Broker TR; Mestecky J; Chow LT
    Vaccine; 2016 Jun; 34(27):3171-3177. PubMed ID: 27113165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.
    Smith JF; Brownlow M; Brown M; Kowalski R; Esser MT; Ruiz W; Barr E; Brown DR; Bryan JT
    Hum Vaccin; 2007; 3(4):109-15. PubMed ID: 17611417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
    Jagu S; Karanam B; Gambhira R; Chivukula SV; Chaganti RJ; Lowy DR; Schiller JT; Roden RB
    J Natl Cancer Inst; 2009 Jun; 101(11):782-92. PubMed ID: 19470949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.
    Zhai L; Peabody J; Pang YS; Schiller J; Chackerian B; Tumban E
    Antiviral Res; 2017 Nov; 147():116-123. PubMed ID: 28939477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.
    Wang JW; Jagu S; Wang C; Kitchener HC; Daayana S; Stern PL; Pang S; Day PM; Huh WK; Roden RB
    PLoS One; 2014; 9(7):e101576. PubMed ID: 24999962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.
    Draper E; Bissett SL; Howell-Jones R; Waight P; Soldan K; Jit M; Andrews N; Miller E; Beddows S
    PLoS One; 2013; 8(5):e61825. PubMed ID: 23650505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus.
    Wang JW; Wu WH; Huang TC; Wong M; Kwak K; Ozato K; Hung CF; Roden RBS
    J Virol; 2018 Aug; 92(15):. PubMed ID: 29743371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
    Einstein MH; Baron M; Levin MJ; Chatterjee A; Edwards RP; Zepp F; Carletti I; Dessy FJ; Trofa AF; Schuind A; Dubin G;
    Hum Vaccin; 2009 Oct; 5(10):705-19. PubMed ID: 19684472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration.
    Bryan JT; Jansen KU; Lowe RS; Fife KH; McClowry T; Glass D; Brown DR
    J Med Virol; 1997 Nov; 53(3):185-8. PubMed ID: 9365880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.
    Faust H; Toft L; Sehr P; Müller M; Bonde J; Forslund O; Østergaard L; Tolstrup M; Dillner J
    Vaccine; 2016 Mar; 34(13):1559-1565. PubMed ID: 26896686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay.
    Brown DR; Garland SM; Ferris DG; Joura E; Steben M; James M; Radley D; Vuocolo S; Garner EI; Haupt RM; Bryan JT
    Hum Vaccin; 2011 Feb; 7(2):230-8. PubMed ID: 21307649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL; Joura EA
    BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
    Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
    Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation.
    Kwak K; Jiang R; Jagu S; Wang JW; Wang C; Christensen ND; Roden RB
    PLoS One; 2013; 8(3):e60507. PubMed ID: 23536912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine.
    Godi A; Panwar K; Haque M; Cocuzza CE; Andrews N; Southern J; Turner P; Miller E; Beddows S
    Vaccine; 2019 Apr; 37(18):2455-2462. PubMed ID: 30926298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11.
    Smith JF; Kowalski R; Esser MT; Brown MJ; Bryan JT
    Hum Vaccin; 2008; 4(2):134-42. PubMed ID: 18388490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies.
    Yeager MD; Aste-Amezaga M; Brown DR; Martin MM; Shah MJ; Cook JC; Christensen ND; Ackerson C; Lowe RS; Smith JF; Keller P; Jansen KU
    Virology; 2000 Dec; 278(2):570-7. PubMed ID: 11118379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial.
    Toft L; Storgaard M; Müller M; Sehr P; Bonde J; Tolstrup M; Østergaard L; Søgaard OS
    J Infect Dis; 2014 Apr; 209(8):1165-73. PubMed ID: 24273179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human papillomavirus type 31b infection of human keratinocytes does not require heparan sulfate.
    Patterson NA; Smith JL; Ozbun MA
    J Virol; 2005 Jun; 79(11):6838-47. PubMed ID: 15890923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacterially expressed human papillomavirus type 6 and 11 bivalent vaccine: Characterization, antigenicity and immunogenicity.
    Pan H; Li Z; Wang J; Song S; Wang D; Wei M; Gu Y; Zhang J; Li S; Xia N
    Vaccine; 2017 May; 35(24):3222-3231. PubMed ID: 28483196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.